ALSYMPCA Trial: Updated Analysis of Survival With Radium-223 Treatment in Metastatic Prostate CancerMatthew Stenger
PD24-07 EFFICACY AND SAFETY OF RADIUM-223 BY RADICAL LOCAL THERAPY AT INITIAL DIAGNOSIS: A RETROSPECTIVE SUBGROUP ANALYSIS OF ALSYMPCA TRIAL 来自 学术范 喜欢 0 阅读量: 7 作者:L Klotz,C Sweeney,A Dicker,N Vogelzang,M Morris,F Verholen,V Wagner,C Lu,C Parker,O Sartor ...
摘要: 770PREASONS FOR PATIENTS (PTS) DISCONTINUING STUDY TREATMENT (TX) IN THE PHASE 3 ALSYMPCA TRIAL OF RADIUM-223 DICHLORIDE (RA-223) IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES (METS)DOI: 10.1093/annonc/mdu336.18 被引量: 1 ...
O'Sullivan J, Widmark DCJ, Syndikus I, James N, Dall'Oglio M, et al. Hematologic safety of radium‑223 dichloride (Ra‑223) in the phase 3 ALSYMPCA trial in castration‑resistant prostate cancer (CRPC) patients with bone metastases: baseline p...
EBRT Use and Safety with Radium-223 in Patients with CRPC and Symptomatic Bone Metastases from the ALSYMPCA Trial Professor Sartor presents results from the ALSYMPCA trial which showed radium-223 significantly reduced the risk of EBRT use for bone pain while significant...
Radium-223 Chloride Safety and Use of External Beam Radiation Therapy (EBRT) in the Phase III Randomized Trial (ALSYMPCA) in Patients With Castration-resistant Prostate Cancer (CRPC) and Bone MetastasesPurpose/Objective(s) Radium-223 chloride (Ra-223), a targeted alpha-emitter, is a calcium ...
PO-0737: Effects of Radium-223 Dichloride on Health-Related QOL in CRPC Pts with Bone Mets from the Ph 3 ALSYMPCA Trialannealingcobaltferromagnetic materialsmagnetic domainsmagnetic particlesmagnetisationnanostructured materialsnickelparticle size20 C...
Vogelzang NJ, Coleman RE, Michalski JM, Nilsson S, O'Sullivan JM, Parker C, et al. Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA Trial. Clin Genitourin Cancer 2017; 15:42.e8-52.e8....
Results The available data suggested the following important difference ranges: 2 to 4 points for the Prostate Cancer Subscale, 5.5 to 8.5 points for the Trial Outcome Index, 1 to 1.5 points for the 3‐item Pain Scale, 1 to 2 points for the 4‐item Pain Scale, 4 to 6 points for the...
Methods Using data from the phase 3 Alpharadin in Symptomatic Prostate Cancer Patients trial, this study estimated important change scores on the FACT-P and the NFPSI-17 via a combination of distribution- and anchor-based methods. These data were also used to establish evidence for the validity...